Therapeutic cancer vaccine delivered with the PharmaJet Needle-free System
GOLDEN, Colo. — June 21, 2022 — PharmaJet®, a biotech company that has developed a more effective way of administering drugs and biologics with their innovative, needle-free injection technology, announced that its partner, Nykode Therapeutics announced positive interim results from its phase 2 trial of their novel candidate, VB10.16, in combination with checkpoint inhibitor atezolizumab for treating ad-vanced cervical cancer. The DNA-based therapeutic cancer vaccine is delivered with the PharmaJet needle-free injection technology.
HPV is the cause of 630,000 cases of cancers annually1 and HPV16 is the predominant cause. To address this, Nykode Therapeutics is continuing to advance their cervical cancer program with their therapeutic DNA immunotherapy (VB10.16) targeting malignancies caused by the cancer inducing Human Papillomavirus 16 (HPV16). The PharmaJet Needle-free Injection System is proven to increase vaccine effectiveness and in addition was chosen by Nykode for it’s conven-ient ease of use.
The interim results demonstrate evidence of anti-tumor activity in a population of heavily pre-treated patients with late-stage cervical cancer. The majority of patients experienced a clinical benefit, and many had durable responses, indicating that VB10.16 may give a meaningful added clinical benefit compared to the existing standard of care treatment in this setting.
Chris Cappello, President and CEO, PharmaJet commented, “We are encouraged by the phase 2 clinical trial results, and continued expansion of the Nykode clinical trials using our Needle-free Injection System. The number of disease applications for DNA vaccines and therapeutics using our delivery systems continues to grow. This is another example of how our needle-free systems are helping novel DNA technologies move successfully into early and late-stage clinical trials.”
For more information about PharmaJet visit www.pharmajet.com.
Refer to Instructions for Use to ensure safe injections and to review risks.
1 HPV New Zealand project; HPV and Cancer, https://www.hpv.org.nz/about-hpv/hpv-and-cancer
PharmaJet’s mission is to enable greater access to life improving pharmaceuticals. PharmaJet’s Needle-free Injection Systems provide increased vaccine effectiveness, a preferred patient and caregiver experience, and a proven path to commercialization. They are also safe, fast, and easy-to-use. The Stratis® System has U.S. FDA 510(k) marketing clearance, CE Mark, and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. The Tropis® System has CE Mark and WHO PQS certification for intradermal injections. For more information visit www.pharmajet.com. Follow us on LinkedIn.